Washington, DC – June 5, 2012
McKinsey & Company named Health Decisions Inc., the leading clinical research organization in Agile Clinical Trials, one of four companies that are shaking up traditional approaches to Health Data. Health Decisions received the honor at the Health Data Initiative Forum 2012.
McKinsey credits Health Decisions as a CRO:
- Leveraging sophisticated Bayesian methods to reduce clinical trial duration, size and costs
- Creating digital software platforms collecting live data from trial sites and applicant pools to streamline trial operations
- Being used currently by multiple pharmaceutical companies in a CRO capacity.
CEO Michael Rosenberg commented, “Health Decisions is honored that McKinsey included us in this esteemed group. We have long believed that real-time access to actionable, role-specific information is essential for conducting successful clinical trials. Only innovative health data systems can provide such access.”
The Health Data Initiative Forum, this year subtitled “Health Datapalooza,” is an annual conference co-hosted by the US Department of Health and Human Services and the Institute of Medicine. The public-private collaboration encourages innovators to utilize health data to develop applications that raise awareness of health system performance and spark community action to improve health.
About Health Decisions
Health Decisions is the leading clinical research organization (CRO) in Agile Clinical Trials, committed to shortening development timelines and maximizing pipeline value for pharmaceutical, biotech and medical device companies. Health Decisions increases R&D productivity through a combination of advanced analytics and quality partnerships that align the interests of Health Decisions and its sponsors. Health Decisions’ Agile Clinical Development methodology provides industry-leading analytics for improved decision making based on near real-time information.
Founded in 1989, Health Decisions is headquartered in Durham, NC, with over 20 years of experience conducting successful clinical studies in Phase I – IV trials including global registration studies.
For more information, contact Courtney Cleaves, Marketing Manager at firstname.lastname@example.org.